Uncategorized

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2023 and provided an update on clinical and corporate developments.

Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates Read More »

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – May 11, 2023

Mirum Pharmaceuticals, Inc. announced that on May 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 20,850 shares of common stock and 10,430 restricted stock units to five new employees under Mirum’s 2020 Inducement Plan.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – May 11, 2023 Read More »

Scroll to Top